Gastrointestinal Diseases  >>  Pexa-Vec (pexastimogene devacirepvec)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
NCT01469611: A Trial of JX-594 in Refractory Colorectal Carcinoma

Completed
1b
15
RoW
JX-594
Samsung Medical Center
Colorectal Carcinoma
10/12
01/15
NCT01380600: Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma

Completed
1b
15
RoW
Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594), JX-594
Jennerex Biotherapeutics, Samsung Medical Center
Carcinoma, Colorectal
11/12
12/15
NCT00629759: A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma

Completed
1
14
RoW
JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
Jennerex Biotherapeutics, Green Cross Corporation
Neoplasms, Liver
07/07
08/07

Download Options